Alla studier
RekryteringFAS2INTERVENTIONELL

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

This study is looking at a new medicine, PF-06835375, for adults who have a blood condition called Immune Thrombocytopenia (ITP). ITP causes low numbers of tiny cells called platelets, which are important for stopping bleeding. We want to find out how safe the medicine is and if it can help increase platelet counts. The study is for people who have had ITP for at least three months and up to or over a year. Participants will receive the medicine as injections under the skin over several months, and researchers will carefully watch how their platelet counts change and if they experience any side effects. This research could help find new ways to manage ITP.

Överblick

Status
Rekrytering
Fas
FAS2
Sponsor
Pfizer
Inskrivningsmål
91
Starta
02 Feb 2022
Beräknad slutförande
02 Aug 2028

Vad handlar denna studie om?

This study is investigating a new medicine named PF-06835375 for adults who have a condition called Primary Immune Thrombocytopenia, often shortened to ITP. ITP is a long-term health issue where your body's immune system mistakenly attacks and destroys its own platelets. Platelets are tiny cells in your blood that help it to clot and stop bleeding, so having too few of them can lead to bruising and bleeding problems.

The main goal of this study is to see if PF-06835375 is safe to use and if it can effectively raise platelet counts in people with ITP. We believe that this medicine might work by affecting certain immune cells, which in turn could lead to more platelets being present in the blood. The study is specifically for people who have had ITP for a while, either for a few months (known as 'persistent' ITP) or for over a year (known as 'chronic' ITP).

Participants will receive the study medicine through injections under the skin. There are different groups in the study, and each will receive a specific dose of the medicine once a month for either three or four months. Throughout this time and afterwards, doctors and nurses will closely monitor participants' health, check their platelet levels, and look for any side effects. This careful monitoring helps us understand how well the medicine works and if it's a good option for treating ITP in the future.

Viktiga punkter

  • This study is for adults (18-70) with Primary Immune Thrombocytopenia (ITP).
  • It's testing a new medicine called PF-06835375 to see if it's safe and increases platelet counts.
  • Participants will receive monthly injections under the skin for 3 or 4 months.
  • The study focuses on people who have had ITP for at least 3 months.
  • Your health and platelet levels will be closely monitored throughout the study.

Vem kan vara berättigad?

To join this study, you need to be an adult between 18 and 70 years old and have been diagnosed with Primary ITP. Your platelet count must be consistently low (below 50 x 10^9/L), and you should have had ITP for at least three months, but no longer than 12 months, or for over 12 months.

There are also some reasons why you wouldn't be able to join. For example, if you've had a significant bleeding event in the past month, or if you currently have bleeding that needs urgent medical treatment or a blood transfusion. Also, if you've had your spleen removed in the last three months, or if you plan to have it removed during the study, you would not be eligible. These rules are in place to help keep everyone in the study safe and to make sure the results are clear.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är du mellan 18 och 70 år gammal?
  2. Have you been diagnosed with Primary ITP?
  3. Is your platelet count consistently low (below 50,000)?
  4. Have you had ITP for at least 3 months, or for over a year?
  5. Have you *not* had any severe bleeding in the last month that needed treatment?
  6. Have you *not* had your spleen removed in the last 3 months, or plan to have it removed soon?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you will receive the study medicine, PF-06835375, as injections under your skin. Depending on which group you are in, you will get these injections once a month for either three or four months. During your participation, you will have regular visits to the clinic where doctors and nurses will monitor your health, check your platelet counts through blood tests, and ask about any side effects you might be experiencing. They will also do other assessments to ensure your safety and track how the medicine is working. The total study duration, including the treatment period and follow-up, will be explained by the study team, but the treatment itself lasts approximately 3 to 4 months.

Potentiella risker och fördelar

Taking part in this study might offer a potential benefit if the new medicine helps increase your platelet count and improves your ITP symptoms. However, like all medicines, PF-06835375 may have side effects, which the study team will discuss with you in detail. There is always a risk that the medicine might not work for you, or that you could experience side effects. Your safety and well-being are the top priority. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Platser (31)

  • East Carolina University
    Verifierat postnummer
    Greenville, USA· Rekrytering
  • Liverpool Sjukhus
    Verifierat postnummer
    Liverpool, Australia· Rekrytering
  • South West Radiology
    Verifierat postnummer
    Liverpool, Australia· Rekrytering
  • Slade Pharmacy
    Verifierat postnummer
    Mount Kuring-Gai, Australia· Rekrytering
  • Calvary Mater Newcastle
    Verifierat postnummer
    Waratah, Australia· Rekrytering
  • Flinders medicinska centrum
    Verifierat postnummer
    Bedford Park, Australia· Rekrytering
  • ICON Cancer Centre - Kurralta Park
    Verifierat postnummer
    Kurralta Park, Australia· Rekrytering
  • The Alfred Hospital
    Verifierat postnummer
    Melbourne, Australien· Rekrytering
  • Royal Perth Hospital
    Verifierat postnummer
    Perth, Australia· Rekrytering
  • Unity Health Toronto, St. Michael's Hospital
    Verifierat postnummer
    Toronto, Kanada· Rekrytering
  • McGill University Health Centre
    Verifierat postnummer
    Montreal, Kanada· Rekrytering
  • Fakultni nemocnice Hradec Kralove
    Verifierat postnummer
    Hradec Králové, Tjeckien· Rekrytering

Vanliga frågor

What is ITP?

ITP stands for Immune Thrombocytopenia. It's a condition where your body's immune system mistakenly attacks and destroys its own platelets, which are cells that help your blood clot.

Vad är en 'Fas 2'-studie?

A Phase 2 study is a stage of clinical research where a new medicine is tested on a larger group of people to see if it works and to check for any side effects before it can be studied further.

Hur kommer medicinen att ges?

The study medicine, PF-06835375, will be given as injections under the skin, usually once a month for a few months.

Kommer jag att veta om jag får den riktiga medicinen?

This study is 'open-label,' which means both you and the study team will know that you are receiving the study medicine, PF-06835375.

Hur länge varar behandlingen?

The treatment period for this study will last for either three or four months, depending on the dose group you are in.

Hur du får reda på mer

Pfizer CT.gov Callcenter

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "Safety and Efficacy Study of PF-06835375 in Primary Immune T…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.